Head-to-head · Cost-Efficiency Index
Ivim Health vs NovoCare Pharmacy
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Ivim Health
Cost-first shoppers who want a compounded GLP-1 quoted with the program charge folded in rather than added at checkout.
Visit Ivim HealthNovoCare Pharmacy
Patients who already have a Wegovy prescription and want the lowest-cost manufacturer-direct self-pay or insurance-copay price — not a fit for readers still looking for a prescriber.
Visit NovoCare PharmacyThe verdict
Ivim Health and NovoCare Pharmacy tie on the Cost-Efficiency Index at 57/100, so neither wins outright on the numbers. For most shoppers we'd start with Ivim Health (ranked #305, a hair above #309) — Cost-first shoppers who want a compounded GLP-1 quoted with the program charge folded in rather than added at checkout. But NovoCare Pharmacy is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Ivim Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Ivim Health | NovoCare Pharmacy |
|---|---|---|
| Cost-Efficiency Index | 57/100 | 57/100 |
| Semaglutide / mo | $149/mo (starting dose, medication and program fee, compounded) | Not disclosed |
| Tirzepatide / mo | $224/mo (starting dose, medication and program fee, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $1,788 | — |
| Tirzepatide / yr (modeled) | $2,688 | — |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #305 | #309 |
Ivim Health
57/100Where the value is
- Both molecules are priced on one page, each quoted as medication and program charge included rather than as a bare drug price
- A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
- The first month of the membership is free
The tradeoffs
- A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
- The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
Regulatory note: the FDA issued a warning letter to Ivim Services LLC dba Ivim in February 2026. We still list and link to Ivim Health; you should know the letter is on the public record before you decide.
NovoCare Pharmacy
57/100Where the value is
- First-party Novo Nordisk program — the most authoritative source for actual Wegovy self-pay and insurance-copay pricing, with no telehealth-platform markup
- Commercially-insured patients can pay as little as $25/month, capped at $100/month in savings
- New oral 'Wegovy Pill' option now available from $149/month, in addition to the injectable pen
The tradeoffs
- This is NOT a telehealth or prescribing service — it requires a valid Wegovy prescription obtained elsewhere, with no consultation or clinical support included
- Introductory pricing is time-limited: the $199/month pen offer expires 12/31/2026 (reverting to $349/month) and the 4mg pill price updates 8/31/2026
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.